Zoetis Inc. | Cash Flow

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
503
587
339
819
862
1,424
Depreciation, Depletion & Amortization
209
204
199
240
242
308
Other Funds
2,743
2
-
32
7
58
Funds from Operations
785
783
872
1,152
1,375
1,678
Changes in Working Capital
104
157
208
439
29
112
Net Operating Cash Flow
681
626
664
713
1,346
1,790
Capital Expenditures
184
195
224
216
224
Sale of Fixed Assets & Businesses
9
9
2
90
37
Net Investing Cash Flow
179
187
1,115
214
313
Cash Dividends Paid - Total
98
146
168
188
206
Issuance/Reduction of Debt, Net
2,641
8
1,115
408
481
Net Financing Cash Flow
200
154
755
903
208
Net Change in Cash
293
272
272
427
837
Free Cash Flow
497
446
440
497
1,122
Deferred Taxes & Investment Tax Credit
23
49
85
55
127
112
Net Assets from Acquisitions
4
-
883
88
125
Change in Capital Stock
-
2
192
275
476
Exchange Rate Effect
9
13
32
23
12
Other Uses
-
1
10
-
1

About Zoetis

View Profile
Address
10 Sylvan Way
Parsippany New Jersey 07054
United States
Employees -
Website http://www.zoetis.com
Updated 07/08/2019
Zoetis, Inc. discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.